The Europe Age Related Macular Degeneration (AMD) Market would witness market growth of 5.0% CAGR during the forecast period (2023-2030).
The macula, a region of the retina responsible for central vision, is impacted by age-related macular degeneration (AMD), a degenerative eye condition. As a person ages, the cells in the macula suffer damage and start to die, which results in vision loss. Wet age-related macular degeneration (AMD) and dry age-related macular degeneration (AMD) are the main illness classifications. Wet AMD is less common and involves the development of abnormal blood vessels beneath the macula. In contrast, dry AMD is more prevalent and involves the creation of small, yellow deposits in the macula.
Treatment options for dry AMD include vitamin supplements and lifestyle modification to lower risk factors. To treat wet AMD, eye injections of drugs are used to prevent the development of abnormal blood vessels. This medicine, known as aberrant endothelial growth factor (anti-VEGF) therapy, stops the protein from promoting the development of abnormal blood vessels. The market is essential to solving the problem of visual loss that the senior population faces.
Nearly one in seven UK residents are expected to be over the age of 75 by 2040, according to a government assessment titled “Future of an aging population” (UK). There will be 1.42 million more homes with at least one individual who is 85 years of age or older by 2037, a rise of 161% over the previous 25 years. Over 5.5 million more people will be added to the working-age population between the ages of 50 and the state pension age (SPA), from 26% in 2012 to 34% in 2050. According to a UN assessment of France aging policy, France, like other European nations, is experiencing a steady and large rise in the population of senior people. In 2012, there were 15 million persons in France over the age of 60. In 2060, this number will increase to 24 million. It is anticipated that the market will grow because of the aging populations in these regional nations.
The Germany market dominated the Europe Age Related Macular Degeneration (AMD) Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $842 million by 2030. The UK market is exhibiting a CAGR of 4.1% during (2023 - 2030). Additionally, The France market would experience a CAGR of 5.7% during (2023 - 2030).
Based on Drug Type, the market is segmented into Aflibercept, Ranibizumab and Others. Based on Disease Type, the market is segmented into Wet and Dry. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide Age Related Macular Degeneration (AMD) Market is Projected to reach USD 13.9 Billion by 2030, at a CAGR of 5.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Biogen, Inc., Bayer AG, Apellis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Ionis Pharmaceuticals, Inc., Novartis AG, Sanofi S.A., Coherus Biosciences, Inc. and Bausch Health Companies, Inc.
By Drug Type
By Disease Type
By Distribution Channel
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 